Ambit Biosciences signs drug-development deal with Astellas

12/23/2009 | North County Times (Temecula, Calif.)

Astellas Pharma will pay Ambit Biosciences $40 million upfront and as much as $350 million in milestone fees as part of a drug-development collaboration. The partnership covers an acute myeloid leukemia treatment, which is in midstage trials, and other drugs that target an enzyme called FLT3 kinase.

View Full Article in:

North County Times (Temecula, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC